Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15922927 | 1.00 | MEN1 (0.54) | MEN1LMNAHTTKMT2AHRH3 | |
| SCHEMBL7388659 | 1.00 | MEN1 (0.54) | MEN1LMNAHTTKMT2AHRH3 | |
| SCHEMBL3098656 | 0.98 | MEN1 (0.51) | MEN1LMNAHTTKMT2AHRH3 | |
| SCHEMBL27517121 | 0.92 | MEN1 (0.49) | MEN1LMNAHTTKMT2AHRH3 | |
| SCHEMBL1427333 | 0.91 | DRD2 (0.50) | MEN1LMNAHTTKMT2AHRH3 | |
| SCHEMBL14095592 | 0.89 | PRMT1 (0.54) | HRH3DRD3CYP2D6L3MBTL1PRMT1 | |
| SCHEMBL30209074 | 0.89 | PRMT1 (0.54) | HRH3DRD3CYP2D6L3MBTL1PRMT1 | |
| SCHEMBL29864772 | 0.89 | PRMT1 (0.54) | HRH3DRD3CYP2D6L3MBTL1PRMT1 | |
| SCHEMBL30720430 | 0.89 | PRMT1 (0.54) | HRH3DRD3CYP2D6L3MBTL1PRMT1 | |
| SCHEMBL9361193 | 0.88 | LSS (0.59) | LMNAHRH3KDM4ESMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706739-B2 | TREATING ENTEROVIRUS INFECTION | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2004-03-16 | — | — | US | disclosed |
| US-20030087936-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2003-05-08 | — | — | US | disclosed |
| CN-1103338-C | Heterocyclic compounds for treating myocardial ischaemia | PF MEDICAMENT (FR) | 2003-03-19 | — | — | CN | disclosed |
| EP-0842174-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PF MEDICAMENT (FR) | 2001-10-04 | — | — | EP | disclosed |
| US-6011032-A | Heterocyclic compounds for treating myocardial ischemia | PIERRE FABRE MEDICAMENT (FR) | 2000-01-04 | — | — | US | disclosed |
| CN-1193972-A | Heterocyclic compounds for treating myocardial ischaemia | PF MEDICAMENT (FR) | 1998-09-23 | — | — | CN | disclosed |
| EP-0842174-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PIERRE FABRE MEDICAMENT (FR) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997005134-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA | PIERRE FABRE MEDICAMENT (FR) | 1997-02-13 | — | — | WO | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087936-A1 | Imidazolidinone compounds | EIF2AK2, ZC3HAV1, EMG1 | MEN1 148/4885LMNA 1948/4885HTT 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.